If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

The job cuts reflect the normal maturation of companies such as Alameda-based Scribe, which is moving from a preclinical to ...